Pharma intelligence Evaluate Ltd operates in high-demand pharmaceutical market intelligence and forecasting, presenting a sales opportunity to upsell comprehensive analytics, Omnium forecasting, and Evaluate Pharma products to pharma companies seeking deeper market insight and future performance outlooks.

CDMO expansion With the October 2023 launch of CDMO Intelligence, there is a demonstrated push into contract development and manufacturing organization data and forecasting; target mid-to-large biopharma firms and CDMOs looking to optimize development timelines and capacity planning.

Strategic partnerships As a Norstella company, Evaluate has established alliances that amplify credibility; identify co-selling or integration opportunities with sister platforms and leverage joint go-to-market for broader asset and portfolio strategy offerings.

Forecasting leadership Evaluate Omnium has received awards for decision management and forecasting excellence; pitch to asset teams, commercial strategists, and portfolio planners who require machine-learning powered risk-adjusted forecasting across product life cycles.

Global reach, mid-market focus With over 50 employees and revenues in the range of 10-25 million, Evaluate sits between mid-size firms and giants; approach mid-market biopharma companies and CROs seeking scalable, cloud-based forecasting and data-rich market intelligence solutions.